• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc. (Amendment)

    2/13/23 4:28:44 PM ET
    $SXTC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTC alert in real time by email
    SC 13G/A 1 sc13ga.htm AMENDMENT NO. 1
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 1)*
     

     
    China SXT Pharmaceuticals, Inc.
     
     
    (Name of Issuer)
     

     
    Ordinary Shares, $0.004 par value per share
     
     
    (Title of Class of Securities)
     

     
    G2161P132
     
     
    (CUSIP Number)
     

     
    December 31, 2022
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Fund II LP

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power

    0
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    0
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0.0%
     
    12
    Type of Reporting Person (See Instructions)

    PN
     
    (1) The reporting person’s ownership consists of 0 common shares


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Partners II LLC

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    0
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    0(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0%
     
    12
    Type of Reporting Person (See Instructions)

    OO
     
    (1) The reporting person’s ownership consists of 0 common shares.


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    0
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
    0(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    0%
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     
    (1) The reporting person’s ownership consists of 0 common shares.


    Item 1.
     
    (a)
    Name of Issuer
       
     
    China SXT Pharmaceuticals, Inc.
     
    (b)
    Address of Issuer’s Principal Executive Offices
       
     
    178 Taidong Rd. North, Taizhou
    Jiangsu, China

    Item 2.
     
    (a)
    Name of Person Filing
       
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •            Lind Global Fund II LP, a Delaware limited partnership;
    •            Lind Global Partners II LLC, a Delaware limited liability company; and
    •            Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
     
    (b)
    Address of Principal Business Office or, if none, Residence
       
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
     
    (c)
    Citizenship
       
     
    See Row 4 of cover page for each Reporting Person.
     
     
    (d)
    Title of Class of Securities
     
       
    Ordinary shares, par value $0.004 per share
     
     
    (e)
    CUSIP Number
       
     
    G2161P132


    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
    (a)
    Amount Beneficially Owned
       
     
    See Row 9 of cover page for each Reporting Person.
     
     
    (b)
    Percent of Class
       
     
    See Row 11 of cover page for each Reporting Person.
     

     
    (c)
    Number of shares as to which such person has:
     
       
    (i)
    sole power to vote or to direct the vote
         

    See Row 5 of cover page for each Reporting Person.
     
       
    (ii)
    shared power to vote or to direct the vote
         
     
    See Row 6 of cover page for each Reporting Person.
     
       
    (iii)
    sole power to dispose or to direct the disposition of
         

    See Row 7 of cover page for each Reporting Person.
     
       
    (iv)
    shared power to dispose or to direct the disposition of
         
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.


    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit
    99.1
    Joint Filing Application by and among the Reporting Persons




    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 13, 2023
    LIND GLOBAL FUND II LP
     
       
    By:
    Lind Global Partners II LLC
     
     
    its General Partner
     
         
    By:
    /s/ Jeff Easton
     
    Name:
    Jeff Easton
     
    Title:
    Managing Member
     
       
    LIND GLOBAL PARTNERS II LLC
       
    By:
    /s/ Jeff Easton
    Name:
    Jeff Easton
    Title:
    Managing Member
       
    JEFF EASTON
     
       
    By:
     
    /s/ Jeff Easton
     


    Get the next $SXTC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SXTC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SXTC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency

      TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that the Company received a written notification (the "Compliance Notice") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated March 13, 2025, informing the Company that it has regained compliance with the Nasdaq Listing Ru

      3/17/25 8:30:00 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China SXT Pharmaceuticals, Inc. Announces Share Consolidation

      TAIZHOU, China, Feb. 21, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (NASDAQ:SXTC) (the "Company" or "SXTC"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that it will effect a share consolidation of its ordinary shares at a ratio of 1-for-8, effective on February 25, 2025 (the "Share Consolidation"). The Company's ordinary shares are expected to begin trading on a post-consolidation basis at the open of th

      2/21/25 12:35:28 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

      Jiangsu, China, , Oct. 07, 2024 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ:SXTC) announced today that on October 3, 2024, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2). The notification received has no immediate effect on the listing of the Company's ordinary shares on Nasdaq. Under the Nasdaq List

      10/7/24 4:15:00 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTC
    SEC Filings

    See more
    • SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.

      424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/19/25 8:00:24 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by China SXT Pharmaceuticals Inc.

      6-K - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/13/25 11:30:25 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.

      424B5 - China SXT Pharmaceuticals, Inc. (0001723980) (Filer)

      5/7/25 7:58:31 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTC
    Leadership Updates

    Live Leadership Updates

    See more
    • Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

      XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

      4/25/23 8:30:00 AM ET
      $BON
      $SXTC
      $WSG
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Services-Misc. Amusement & Recreation

    $SXTC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      10/25/24 12:19:29 PM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc.

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      8/15/24 9:45:36 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by China SXT Pharmaceuticals Inc. (Amendment)

      SC 13G/A - China SXT Pharmaceuticals, Inc. (0001723980) (Subject)

      5/31/24 10:36:52 AM ET
      $SXTC
      Biotechnology: Pharmaceutical Preparations
      Health Care